Accordingly, the inter-twin difference in IL-2 expression was significantly higher in twin pairs in which the twin with MS had entered the more-advanced phase of disease progression known as secondary progressive MS, than twin pairs in which the affected twin was in a relapsing–remitting stage (RRMS) (Fig. 3h, Extended Data Fig. 5j). This evidence concerns the gene IL2 and myeloid sarcoma.